

---

**Neuland Laboratories Limited**

Sanali Info Park, 'A' Block,  
Ground Floor, 8-2-120/113  
Road No. 2, Banjara Hills  
Hyderabad - 500 034.  
Telangana, India.

Tel: 040 3021 1600 / 23551081  
Fax: 040 30211602  
Email: [neuland@neulandlabs.com](mailto:neuland@neulandlabs.com)  
[www.neulandlabs.com](http://www.neulandlabs.com)

---

October 26, 2018

To  
B S E Limited  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai - 400 001

**Scrip Code: 524558**

To  
The National Stock Exchange of India Ltd  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E)  
Mumbai - 400 001

**Scrip Code: NEULANDLAB**  
**Series: EQ**

Dear Sirs,

**Results Release and Earnings Call Notice**

We refer to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 and enclose a copy of the Q2 FY 2019 Earnings Call details, for your information and records.

Thanking you,

Yours faithfully,  
For Neuland Laboratories Limited



**Sarada Bhamidipati**  
**Company Secretary**

Encl:a/a



**Neuland Laboratories Limited's Q2 FY 2018-19 Results Conference Call**  
**At 15:30 hrs. IST on November 2, 2018**

Neuland Laboratories Limited will announce its results for the quarter ended September 30, 2018 on November 2, 2018. The results will also be made available on the website of the Company, [www.neulandlabs.com](http://www.neulandlabs.com).

Following the announcement, the management of the Company will host an Earnings Call on the same day at 15:30 hrs. The details of the earnings call are:

**Date: November 2, 2018**

**Time: 15:30 Hrs.**

**Dial-in Number: +91 22 6629 0021 / +91 22 7194 5721**

You can also [click here for the diamond pass and calendar invite to your inbox](#)

**Other Numbers:**

**Local Access Number**

+91 70456 71221 (Available all over India)

**International Toll-Free Number**

USA - 18667462133 | UK - 08081011573 | Singapore - 8001012045 | Hong Kong - 800964448

**About Neuland Laboratories Limited (BSE:524558, NSE: NEULANLAB)**

For over 34 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs, and it has filed around 56 U.S. drug master files (USDMFs) and over 650 Regulatory filings in the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the USFDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), Health Canada, CFDA (China) ISO 9001, ISO14001, OHSAS18001 and ISO 27001.

For more information, visit [www.NeulandLabs.com](http://www.NeulandLabs.com).

For Queries:

Neuland: [ir@neulandlabs.com](mailto:ir@neulandlabs.com) or Diwakar Pingle: [dpingle@christensenir.com](mailto:dpingle@christensenir.com)